potential COVID-19 treatments for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 15

table network network 2

display ongoing demontrated benefit only

click on circles to display study description...

Zhao, 2021

favipiravir (n=36) vs. standard of care (n=19)

randomized controlled trial

Studied treatment

favipiravir
ffavipiravir was 1600 mg (bid) on the first day, and 600 mg (bid) from the 2nd day to the 7th day, orally

Control treatment

standard of care

Patients

preventing respiratory virus transmission

Method

Open-label.

Multicenter, China

Remark

powered by vis.js Network

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open